Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
- Revenue in EUR (TTM)70.94m
- Net income in EUR1.51m
- Incorporated1999
- Employees180.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novacyt SA | 22.77m | -44.89m | 33.57m | 234.00 | -- | 0.6037 | -- | 1.47 | -0.6356 | -0.6859 | 0.3224 | 0.7874 | 0.192 | -4.70 | 1.29 | 97,317.76 | -37.86 | 5.59 | -45.89 | 7.29 | 163.39 | 66.74 | -197.14 | 9.83 | 5.97 | -5.26 | 0.1988 | -- | 84.82 | 11.35 | -60.50 | -- | 55.60 | -- |
| Abionyx Pharma SA | 4.55m | -4.38m | 42.27m | 51.00 | -- | 5.58 | -- | 9.29 | -0.13 | -0.13 | 0.1351 | 0.2167 | 0.3208 | 17.16 | 4.77 | 89,235.30 | -30.88 | -26.53 | -42.24 | -38.31 | 18.55 | 15.59 | -96.26 | -131.06 | 1.52 | -- | 0.2684 | -- | -1.92 | -- | -24.53 | -- | -- | -- |
| Fermentalg SA | 11.50m | -12.88m | 45.10m | 64.00 | -- | 1.39 | -- | 3.92 | -0.1759 | -0.1759 | 0.1545 | 0.362 | 0.2268 | 2.29 | 6.01 | 179,640.60 | -19.25 | -18.10 | -22.53 | -20.59 | 21.70 | 25.51 | -84.89 | -147.66 | 2.40 | -256.97 | 0.2778 | -- | 183.32 | 43.52 | 8.99 | -- | -4.91 | -- |
| Adocia SA | 9.32m | -9.32m | 69.83m | 77.00 | -- | -- | -- | 7.49 | -0.6483 | -0.6483 | 0.6294 | -0.1977 | 0.3586 | -- | 2.14 | 121,039.00 | -35.87 | -47.62 | -164.77 | -104.50 | -- | -- | -100.01 | -331.17 | 1.07 | -8.90 | 1.35 | -- | 333.49 | 34.18 | 55.95 | -- | -35.29 | -- |
| Maat Pharma SA | 3.22m | -28.90m | 74.13m | 60.00 | -- | 6.22 | -- | 23.05 | -2.21 | -2.21 | 0.2462 | 0.7395 | 0.079 | 9.84 | 3.83 | 53,600.00 | -70.99 | -41.51 | -104.45 | -51.87 | 61.13 | -- | -898.79 | -976.99 | 1.89 | -32.75 | 0.6069 | -- | 44.34 | -- | -46.59 | -- | 42.53 | -- |
| Eurofins-Cerep SA | 40.46m | 7.15m | 88.77m | 207.00 | 12.41 | 1.24 | 9.28 | 2.19 | 1,418.43 | 1,418.43 | 8,027.24 | 14,234.14 | 0.4955 | 1.61 | 4.75 | 195,445.80 | 8.76 | 13.12 | 10.23 | 15.90 | 85.67 | 80.02 | 17.68 | 20.22 | 6.53 | -- | 0.0046 | -- | -8.20 | 5.46 | -6.34 | 10.36 | -- | -- |
| Cellectis SA | 46.79m | -51.74m | 96.18m | 224.00 | -- | 0.9711 | -- | 2.06 | -0.555 | -0.555 | 0.4908 | 1.37 | 0.1524 | -- | 4.58 | 208,897.80 | -16.59 | -21.50 | -29.99 | -29.24 | -- | -32.79 | -108.88 | -220.86 | -- | -7.06 | 0.442 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Sensorion SA | 0.00 | -25.97m | 98.02m | 63.00 | -- | 1.36 | -- | -- | -0.0923 | -0.0923 | 0.00 | 0.2401 | 0.00 | -- | -- | 0.00 | -38.26 | -34.53 | -46.44 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0285 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| Transgene SA | 6.08m | -33.97m | 104.33m | 165.00 | -- | 6.82 | -- | 17.16 | -0.1633 | -0.1633 | 0.0523 | 0.1152 | 0.1392 | -- | 6.19 | 36,854.55 | -77.74 | -33.32 | -107.22 | -40.55 | -- | -- | -558.64 | -251.37 | -- | -- | 0.4023 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Ose Immunotherapeutics SA | 83.44m | 37.45m | 116.38m | 64.00 | 3.72 | 1.74 | 2.86 | 1.39 | 1.37 | 1.37 | 3.55 | 2.91 | 0.81 | -- | 32.59 | 1,303,672.00 | 36.35 | -7.66 | 44.85 | -9.27 | -- | -- | 44.88 | -26.10 | -- | 14.19 | 0.4196 | -- | 3,646.52 | 26.31 | 262.78 | -- | -25.52 | -- |
| Innate Pharma SA | 12.62m | -49.47m | 139.38m | 168.00 | -- | 14.34 | -- | 11.04 | -0.61 | -0.61 | 0.1556 | 0.1054 | 0.0882 | -- | 0.4171 | -- | -34.57 | -13.29 | -46.32 | -17.34 | 52.73 | -- | -391.94 | -88.46 | -- | -- | 0.9001 | -- | -75.68 | -28.80 | -553.51 | -- | -64.08 | -- |
| Genfit SA | 70.94m | 1.51m | 165.81m | 180.00 | 91.50 | 2.39 | 51.10 | 2.34 | -0.0716 | -0.0716 | 1.28 | 1.38 | 0.4362 | 512.25 | 5.44 | 394,105.60 | 0.9265 | -7.73 | 1.42 | -9.79 | 97.11 | 95.68 | 2.12 | -37.15 | 1.23 | 1.45 | 0.473 | -- | 85.82 | 11.61 | 105.22 | -- | -13.57 | -- |
| Nanobiotix SA | -11.61m | -68.13m | 218.46m | 108.00 | -- | -- | -- | -- | -1.44 | -1.44 | -0.2456 | -1.39 | -0.1439 | -- | -- | -107,490.70 | -84.47 | -54.39 | -259.52 | -90.60 | -- | -- | -- | -1,326.20 | -- | -27.67 | -- | -- | -138.62 | -- | -71.62 | -- | -10.10 | -- |
Data as of Jul 11 2025. Currency figures normalised to Genfit SA's reporting currency: Euro EUR
0.65%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sunny Asset Management SAas of 28 May 2025 | 120.00k | 0.24% |
| CPR Asset Management SAas of 30 Sep 2024 | 109.11k | 0.22% |
| Mandarine Gestion SAas of 31 Dec 2024 | 33.50k | 0.07% |
| OFI Invest Asset Management SAas of 28 May 2025 | 31.13k | 0.06% |
| Dimensional Fund Advisors LPas of 04 Jul 2025 | 18.74k | 0.04% |
| American Century Investment Management, Inc.as of 02 Jul 2025 | 6.91k | 0.01% |
| Gestys SAas of 28 Mar 2025 | 4.10k | 0.01% |
| Friedland Gestion SASas of 28 Feb 2025 | 1.80k | 0.00% |
| Clay Asset Management SASas of 30 Jun 2024 | 0.00 | 0.00% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2025Source: FactSet Research Systems Inc.
